Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation …
U Keilholz, CJA Punt, M Gore, W Kruit… - Journal of clinical …, 2005 - ascopubs.org
Background Based on phase II trial results, chemoimmunotherapy combinations have
become the preferred treatment for patients with metastatic melanoma in many institutions …
become the preferred treatment for patients with metastatic melanoma in many institutions …
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in …
SA Rosenberg, JC Yang… - Journal of Clinical …, 1999 - ascopubs.org
PURPOSE: The combination of chemotherapy with immunotherapeutic agents such as
interleukin-2 and interferon alfa-2b has been reported to provide improved treatment results …
interleukin-2 and interferon alfa-2b has been reported to provide improved treatment results …
Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology …
A Hauschild, C Garbe, W Stolz, U Ellwanger… - British journal of …, 2001 - nature.com
In several phase II-trials encouraging tumour responses rates in advanced metastatic
melanoma (stage IV; AJCC-classification) have been reported for the application of …
melanoma (stage IV; AJCC-classification) have been reported for the application of …
Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and …
J Atzpodien, EL Hänninen, H Kirchner… - European Journal of …, 1995 - Elsevier
Both chemotherapy and interleukin-2 and/or interferon-α produce objective responses in a
proportion of advanced malignant melanoma patients. While duration of response to …
proportion of advanced malignant melanoma patients. While duration of response to …
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of …
U Keilholz, SH Goey, CJ Punt, TM Proebstle… - Journal of clinical …, 1997 - ascopubs.org
PURPOSE The combination of interferon alfa-2a (IFN alpha) and high-dose interleukin-2 (IL-
2) is active in metastatic melanoma. The addition of cisplatin (CDDP) has resulted in …
2) is active in metastatic melanoma. The addition of cisplatin (CDDP) has resulted in …
A multicenter phase II clinical trial using dacarbazine and continuous infusion lnterleukin‐2 for metastatic melanoma. Clinical data and immunomonitoring
R Dummer, G Burg, ME Gore, BW Hancock… - Cancer, 1995 - Wiley Online Library
Background. Treatment of patients with metastatic melanoma with either dacarbazine or
recombinant interleukin‐2 (rIL‐2) resulted in a response rate of approximately 15%. This …
recombinant interleukin‐2 (rIL‐2) resulted in a response rate of approximately 15%. This …
A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin‐2 in metastatic malignant melanoma
LE Flaherty, BG Redman, S Martino, M Kraut… - Cancer, 1993 - Wiley Online Library
Background. Based on prior experience with dacarbazine (DTIC) and an outpatient
interleukin‐2 (IL‐2) regimen, the current study was conducted to improve the antitumor …
interleukin‐2 (IL‐2) regimen, the current study was conducted to improve the antitumor …
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: results from an Italian multicenter phase …
R Ridolfi, V Chiarion-Sileni, M Guida… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and
interferon alfa-2b (IFNα-2b) in multiagent chemotherapy (CT) for advanced melanoma …
interferon alfa-2b (IFNα-2b) in multiagent chemotherapy (CT) for advanced melanoma …
Randomized trial of treatment with cisplatin and interleukin‐2 either alone or in combination with interferon‐α‐2a in patients with metastatic melanoma: A Federation …
T Dorval, S Négrier, C Chevreau, MF Avril, D Baume… - Cancer, 1999 - Wiley Online Library
BACKGROUND The objective of the current study was to evaluate the response rate,
survival, and toxicity of treatment with cisplatin and high dose intravenous continuous …
survival, and toxicity of treatment with cisplatin and high dose intravenous continuous …
Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional …
DB Thomson, M Adena, GR McLeod, P Hersey… - Melanoma …, 1993 - europepmc.org
Following extensive phase II trials of the combination of dacarbazine and interferon-alpha
2a we performed a prospective, randomized, controlled trial of this combination versus …
2a we performed a prospective, randomized, controlled trial of this combination versus …